ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
Year: 2018
Type: article
Institutions: Ospedale Policlinico San Martino, University of Genoa, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Comenius University Bratislava, Universidad Complutense de Madrid, Instituto de Salud Carlos III, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Red Espanola de Investigacion en Patologia Infecciosa, University Hospital Regensburg
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: CD19-targeted therapy, anti-CD20 therapy, blinatumomab, inebilizumab, alemtuzumab, anti-CD20 monoclonal antibody, infection risk, immunosuppression, neutropenia, catheter-related bloodstream infection, HBV reactivation, varicella-zoster virus infection, antiviral prophylaxis, cytomegalovirus infection, leukemia, tuberculosis screening, HCV screening
Open Access status: bronze
OpenAlex ID: W2786511378
